Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer (Q33366124)

26 July 2017

title

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

S T Kim

1

1 reference

26 July 2017

W K Kang

2

1 reference

26 July 2017

J H Kang

3

1 reference

26 July 2017

K W Park

4

1 reference

26 July 2017

J Lee

5

1 reference

26 July 2017

S-H Lee

6

1 reference

26 July 2017

J O Park

7

1 reference

26 July 2017

K Kim

8

1 reference

26 July 2017

W S Kim

9

1 reference

26 July 2017

C W Jung

10

1 reference

26 July 2017

Y S Park

11

1 reference

26 July 2017

Y-H Im

12

1 reference

26 July 2017

K Park

13

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

92

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

1850-1854

1 reference

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

CPT-11 in gastrointestinal cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361777

CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602575

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602575

A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602575

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602575

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602575

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602575

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602575

Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 Hospitals

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15870718

12 December 2020

inferred from PubMed ID database lookup

[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15870718

12 December 2020

inferred from PubMed ID database lookup

Treatment of gastric cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15870718

12 December 2020

inferred from PubMed ID database lookup

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602575

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6602575

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference